Vigil Neuroscience (VIGL) shares surged over 26% in recent Thursday trading following positive results from a Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease, supporting its advancement to a mid-stage clinical trial.
The initial Phase 1 study demonstrated a favorable safety and tolerability profile for VG-3927 across all subjects, including elderly participants.
VG-3927 achieved a dose-dependent reduction of soluble TREM2 levels in cerebrospinal fluid by about 50% and showed activation of the TREM2 receptor, which is believed to support brain health through microglial activity.
Based on these findings, Vigil said it plans to advance a once-daily oral dose of 25 milligrams into a Phase 2 trial, expected to begin in Q3.
Price: 2.56, Change: +0.53, Percent Change: +26.11
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。